Furosemide · FUROSEMIDE 10 mg/mL · Solution · Oral · Atlantic Biologicals Corp.
NDC 17856-3294-01 · 120 SYRINGE in 1 CASE / 3 mL in 1 SYRINGE · ANDA · View full market →
4 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “shortage of an inactive ingredient component”.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Matched to CMS's representative package for this drug (NDC 00054-3294-46) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Atlantic Biologicals Corp. | FUROSEMIDE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Atlantic Biologicals Corps | FUROSEMIDE 40 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | FUROSEMIDE 10 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Hikma Pharmaceuticals USA Inc. | FUROSEMIDE 40 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
| Precision Dose Inc. | FUROSEMIDE 40 mg/4mL | Jul 15, 2026 | Sep 2, 2026 |
| Precision Dose Inc. | FUROSEMIDE 40 mg/5mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Furosemide — NDC 17856-3294-01," retrieved September 3, 2026, https://drugdashboards.com/drug/17856329401.
Free to cite with attribution — see how the data is put together.